{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Randomization and Subject Number Assignment', 'An Interactive Response Technology system (IRT) will be utilized to register subjects.', 'Subjects who complete all Screening procedures and meet the eligibility criteria will', 'proceed to randomization. Refer to Section 5.5.3 for details associated with subject', 'assignment to treatment arms.', 'Health Resource Utilization', 'Health Resource Utilization will be documented at each clinic visit per Appendix C,', 'Study Activities. Information regarding hospitalizations, emergency room visits, and', 'physician office visits will be collected since the last study visit.', 'Patient Reported Outcomes (PRO)', 'Health-related quality of life and symptom assessments will be performed per', 'Appendix C, Study Assessments using the EORTC QLQ-C30, the EORTC QLQ-LC13,', 'and the European Quality of Life-5 Dimensions (EQ-5D-5L). The European Organization', 'for Research and Treatment of Cancer Quality of Life Questionnaire', '(EORTC QLQ-C30) 13 is used as general cancer-specific instrument. The', 'EORTC QLQ-C30 has 30 items and 5 functional domain scales: Physical, Role,', 'Emotional, Social, and Cognitive; two items evaluate global quality of life. The EORTC', 'QLQ-C30 core questionnaire can be supplemented by the additional lung module EORTC', 'QLQ-LC13, resulting in a 43-item disease and cancer site-specific quality of life and', 'symptom questionnaire. The EORTC QLQ-LC13 module items evaluate symptoms such', 'as cough, haemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling', 'hands or feet, hair loss, and pain. The EuroQol 5 Dimensions 5 Level (EQ-5D-5L) is a', 'generic preference instrument that has been validated in numerous populations. The', 'EQ-5D-5L is composed of 5 questions and a visual analog scale (VAS) assessing overall', 'health that can be converted into a single health status or \"utility\" score for use in an', \"economic evaluation to adjust life-years gained by the subject's health-related quality of\", 'life.', '52']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Fluid Retention Questionnaire (Including Subject Daily Weight)', 'Throughout the treatment period as outlined in the Appendix C, Study Activities, subjects', 'will be asked about the development of any new or worsening peripheral edema or', 'dyspnea (Appendix I, Fluid Retention Questionnaire). The assessments on Days 8, 15,', '29, and 36 may take place by phone, with the site contacting the subject and reviewing the', 'questionnaire.', 'Starting on Day 1 through the EOT visit, subjects will maintain a diary of daily weights', '(captured on the Fluid Retention Questionnaire). Subjects should be instructed to use a', 'consistent device throughout the study. The site will advise subjects to contact the site in', 'cases where sudden weight gain (5% or greater) is observed for possible assessment in the', 'clinic.', 'Non-Treatment Cycle Visit', 'In order to establish 12 weeks of non-treatment after two dosing cycles, every third cycle', 'of treatment should be omitted and a clinic visit conducted, as outlined in Appendix C,', 'Study Activities. The visit should be performed after the Disease Response/Assessment', 'has been conducted and reviewed by the Investigator. The subject should continue to', 'complete the Fluid Retention Questionnaire, including conducting daily weight', 'assessments, and the site should contact the subject weekly during this 42 day non-', 'treatment cycle to review the questionnaire and assess for any adverse events or changes', 'in concomitant medications. The following cycle of treatment may be resumed', '42 days 3d if the subject has not met any reason for study treatment discontinuation as', 'outlined in Section 5.4.', 'End of Treatment (EOT) Visit', 'The visit at which an investigator identifies disease progression or a subject meets other', 'criteria for study treatment discontinuation will be considered the End of Treatment Visit.', 'The EOT procedures should be done within 7 days of documented decision to discontinue', 'treatment and prior to subjects beginning any new anti-cancer therapy if possible. The', '53']\n\n###\n\n", "completion": "END"}